Compare Newmont Corporation (NEM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs TransMedics Group Inc — how do they compare? Newmont Corporation trades at $127.91 (market cap $133.91B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Newmont Corporation is far larger — about 43.8× TransMedics Group Inc's market cap, and Newmont Corporation pays a 0.82% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| NEM | TMDX | |
|---|---|---|
Market Cap | $133.91B | $3.06B |
Sector | Basic Materials | Technology |
52-Week High | $135.14 | $150.42 |
52-Week Low | $78.32 | $61.99 |
Enterprise Value | $130.50B | $3.46B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NEM trades at $127.09, down 0.78% on the day, with a bullish technical signal and strong fundamental momentum. Revenue grew to $22.67B in 2025, with net income surging to $7.09B, and Q2 2026 EPS beat expectations at $2.10. Analyst consensus is strongly bullish with a $134.63 price target, supported by record free cash flow and institutional buying.
Outlook remains positive given earnings beats and gold's safe-haven appeal, but production challenges and cost pressures pose risks. The stock offers growth from operational strength and shareholder returns, yet investors face volatility from commodity prices and execution hurdles.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
